Autopsy report · NCT05538624

A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

“Sponsor Decision to close study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 1 year 4 months before it stopped.
• 14 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Avenge Bio, Inc

Sponsor type

Industry

Conditions

Neoplasm, Ovarian; Fallopian Tube Cancer; Primary Peritoneal Cavity Cancer; Adenocarcinoma Ovary; Serous Adenocarcinoma of Ovary; Serous Adenocarcinoma of Primary Peritoneum

Interventions

AVB-001 (Dose Escalation Phase); AVB-001 (Dose Expansion Phase)

Participants

14

Sites

5

Countries

United States

Trials that died the same way

• ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma
  “Sponsor has decided to close study.” (95% match in meaning)
• Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
  “Study sponsor decided to close study.” (94% match in meaning)
• Evaluation of Tissue Oxygen Levels During Breast Reconstruction With a New Surgical Device
  “Sponsor decision to end study.” (88% match in meaning)
• L-Menthol Injection as a Novel Technique During Colonoscopy
  “Sponsor/Investigator has decided to close out the study” (88% match in meaning)
• Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy
  “Sponsor decision to close study early; not due to safety concerns” (88% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.